India · Delayed Price · Currency is INR Anuh Pharma Statistics
Total Valuation
Anuh Pharma has a market cap or net worth of INR 7.69 billion. The enterprise value is 7.16 billion.
| Market Cap | 7.69B |
| Enterprise Value | 7.16B |
Important Dates
The last earnings date was Wednesday, May 20, 2026.
| Earnings Date | May 20, 2026 |
| Ex-Dividend Date | Aug 5, 2026 |
Share Statistics
Anuh Pharma has 100.22 million shares outstanding. The number of shares has decreased by -0.11% in one year.
| Current Share Class | 100.22M |
| Shares Outstanding | 100.22M |
| Shares Change (YoY) | -0.11% |
| Shares Change (QoQ) | -0.54% |
| Owned by Insiders (%) | 72.90% |
| Owned by Institutions (%) | 0.00% |
| Float | 26.86M |
Valuation Ratios
The trailing PE ratio is 18.70.
| PE Ratio | 18.70 |
| Forward PE | n/a |
| PS Ratio | 1.00 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.59, with an EV/FCF ratio of -65.76.
| EV / Earnings | 17.43 |
| EV / Sales | 0.93 |
| EV / EBITDA | 11.59 |
| EV / EBIT | 14.21 |
| EV / FCF | -65.76 |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.00.
| Current Ratio | 2.22 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | -0.01 |
| Interest Coverage | 106.58 |
Financial Efficiency
Return on equity (ROE) is 12.10% and return on invested capital (ROIC) is 12.43%.
| Return on Equity (ROE) | 12.10% |
| Return on Assets (ROA) | 5.91% |
| Return on Invested Capital (ROIC) | 12.43% |
| Return on Capital Employed (ROCE) | 14.21% |
| Weighted Average Cost of Capital (WACC) | 7.03% |
| Revenue Per Employee | 26.16M |
| Profits Per Employee | 1.39M |
| Employee Count | 295 |
| Asset Turnover | 1.45 |
| Inventory Turnover | 5.40 |
Taxes
In the past 12 months, Anuh Pharma has paid 131.75 million in taxes.
| Income Tax | 131.75M |
| Effective Tax Rate | 24.30% |
Stock Price Statistics
The stock price has decreased by -26.05% in the last 52 weeks. The beta is 0.50, so Anuh Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -26.05% |
| 50-Day Moving Average | 78.17 |
| 200-Day Moving Average | 80.90 |
| Relative Strength Index (RSI) | 41.92 |
| Average Volume (20 Days) | 5,191 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Anuh Pharma had revenue of INR 7.72 billion and earned 410.46 million in profits. Earnings per share was 4.10.
| Revenue | 7.72B |
| Gross Profit | 1.72B |
| Operating Income | 503.38M |
| Pretax Income | 542.21M |
| Net Income | 410.46M |
| EBITDA | 617.20M |
| EBIT | 503.38M |
| Earnings Per Share (EPS) | 4.10 |
Balance Sheet
The company has 531.61 million in cash and 583,000 in debt, with a net cash position of 531.03 million or 5.30 per share.
| Cash & Cash Equivalents | 531.61M |
| Total Debt | 583,000 |
| Net Cash | 531.03M |
| Net Cash Per Share | 5.30 |
| Equity (Book Value) | 3.52B |
| Book Value Per Share | 35.28 |
| Working Capital | 2.48B |
Cash Flow
In the last 12 months, operating cash flow was -30.12 million and capital expenditures -78.69 million, giving a free cash flow of -108.80 million.
| Operating Cash Flow | -30.12M |
| Capital Expenditures | -78.69M |
| Depreciation & Amortization | 113.82M |
| Net Borrowing | -108.52M |
| Free Cash Flow | -108.80M |
| FCF Per Share | -1.09 |
Margins
Gross margin is 22.29%, with operating and profit margins of 6.52% and 5.32%.
| Gross Margin | 22.29% |
| Operating Margin | 6.52% |
| Pretax Margin | 7.03% |
| Profit Margin | 5.32% |
| EBITDA Margin | 8.00% |
| EBIT Margin | 6.52% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 1.96%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 1.96% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | 36.47% |
| Buyback Yield | 0.11% |
| Shareholder Yield | 2.07% |
| Earnings Yield | 5.34% |
| FCF Yield | -1.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 15, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Jul 15, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |